# Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

> **NCT02078219** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 204 (actual)

## Conditions studied

- Gout and Hyperuricemia

## Interventions

- **DRUG:** RDEA3170
- **DRUG:** Allopurinol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02078219
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-05
- **Primary completion:** 2015-03-13
- **Final completion:** 2015-03-13
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2019-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02078219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02078219, "Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02078219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*